Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction

Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data suggest that sacubitril/valsartan is associated with i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mauro Gori, James L Januzzi, Emilia D’Elia, Ferdinando L Lorini, Michele Senni
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/f312d9e2247a4d8ab1a5ab02466600bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f312d9e2247a4d8ab1a5ab02466600bc
record_format	dspace
spelling	oai:doaj.org-article:f312d9e2247a4d8ab1a5ab02466600bc2021-12-04T16:04:13ZRationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction10.15420/cfr.2020.252057-75592057-7540https://doaj.org/article/f312d9e2247a4d8ab1a5ab02466600bc2021-04-01T00:00:00Zhttps://www.cfrjournal.com/articleindex/cfr.2020.25https://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data suggest that sacubitril/valsartan is associated with improved outcomes compared with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and has a greater beneficial effect on myocardial reverse remodelling. Additionally, two recent trials have shown that sacubitril/valsartan is well-tolerated even in the acute HF setting, thus enabling a continuum of use in the patient’s journey with HFrEF. This article summarises available data on the effectiveness and tolerability of sacubitril/valsartan in patients with HFrEF, and provides the clinician with practical insights to facilitate the use of this drug in every setting, with an emphasis on acute HF, hypotension, electrolyte imbalance and renal insufficiency.Mauro GoriJames L JanuzziEmilia D’EliaFerdinando L LoriniMichele SenniRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 7, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Mauro Gori James L Januzzi Emilia D’Elia Ferdinando L Lorini Michele Senni Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
description	Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data suggest that sacubitril/valsartan is associated with improved outcomes compared with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and has a greater beneficial effect on myocardial reverse remodelling. Additionally, two recent trials have shown that sacubitril/valsartan is well-tolerated even in the acute HF setting, thus enabling a continuum of use in the patient’s journey with HFrEF. This article summarises available data on the effectiveness and tolerability of sacubitril/valsartan in patients with HFrEF, and provides the clinician with practical insights to facilitate the use of this drug in every setting, with an emphasis on acute HF, hypotension, electrolyte imbalance and renal insufficiency.
format	article
author	Mauro Gori James L Januzzi Emilia D’Elia Ferdinando L Lorini Michele Senni
author_facet	Mauro Gori James L Januzzi Emilia D’Elia Ferdinando L Lorini Michele Senni
author_sort	Mauro Gori
title	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
title_short	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
title_full	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
title_fullStr	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
title_full_unstemmed	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
title_sort	rationale for and practical use of sacubitril/valsartan in the patient’s journey with heart failure and reduced ejection fraction
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/f312d9e2247a4d8ab1a5ab02466600bc
work_keys_str_mv	AT maurogori rationaleforandpracticaluseofsacubitrilvalsartaninthepatientsjourneywithheartfailureandreducedejectionfraction AT jamesljanuzzi rationaleforandpracticaluseofsacubitrilvalsartaninthepatientsjourneywithheartfailureandreducedejectionfraction AT emiliadelia rationaleforandpracticaluseofsacubitrilvalsartaninthepatientsjourneywithheartfailureandreducedejectionfraction AT ferdinandollorini rationaleforandpracticaluseofsacubitrilvalsartaninthepatientsjourneywithheartfailureandreducedejectionfraction AT michelesenni rationaleforandpracticaluseofsacubitrilvalsartaninthepatientsjourneywithheartfailureandreducedejectionfraction
_version_	1718372709782519808

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction

Ejemplares similares